Compare AU
Compare DRUG vs. IHD
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the S&P/ASX Aussie Dividend Opportunities (IHD). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | IHD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 27 |
Median incremental investment | $967.00 | $644.56 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $1,334.92 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | IHD | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | IHD.AX was created on 2010-12-06 by iShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The ETF currently has 317.01m in AUM and 51 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of 50 ASX listed stocks that offer high dividend yields while meeting diversification, profitability and tradability requirements as well as being screened for sustainability considerations |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | RIO TINTO LTD (9.87 %) FORTESCUE LTD (8.72 %) WESTPAC BANKING CORPORATION CORP (8.18 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Financials (42.51 %) Materials (22.84 %) Industrials (13.44 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | Australia (99.25 %) New Zealand (0.75 %) |
Management fee | 0.57 % | 0.23 % |
Key Summary
DRUG | IHD | |
|---|---|---|
Issuer | BetaShares | iShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P/ASX Dividend Opportunities Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.23 % |
Price | $8.12 | $14.51 |
Size | $191.120 million | $315.264 million |
10Y return | N/A | 3.05 % |
Annual distribution yield (5Y) | 1.90 % | 7.42 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 09/12/2010 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | IHD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 27 |
Median incremental investment | $967.00 | $644.56 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $1,334.92 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | IHD | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | IHD |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |